Gossamer Bio announces up to $250M private placement (GOSS:NASDAQ)
· seekingalpha.com
Gossamer Bio (GOSS) plans a $250M private placement tied to seralutinib’s PAH NDA and FDA milestones.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...